Skip to main content
Clinical Trials/NCT05914090
NCT05914090
Not yet recruiting
Not Applicable

The Application of Enhanced Recovery After Surgery (ERAS) for Cardiovascular Surgery in Adult: a Stepped Wedge Cluster Randomized Trial

Yan Fuxia1 site in 1 country3,600 target enrollmentOctober 11, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiac Surgery
Sponsor
Yan Fuxia
Enrollment
3600
Locations
1
Primary Endpoint
Composite outcomes
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

Among adults, patients undergoing elective extracorporeal circulation for cardiac surgery are included in the ERAS strategy intervention plan, which mainly includes preoperative education, preoperative oral intake of multidimensional carbohydrate beverages, multimodal analgesia, blood protection strategies, correction of perioperative hypoalbuminemia, early removal of tracheal intubation, maintenance of blood sugar at reasonable levels, and targeted liquid therapy. The traditional plan group follows the current clinical diagnosis and treatment routine. By comparing the differences in the incidence of major postoperative outcomes (MACCE events, major pulmonary complications, and acute kidney injury) between the intervention group and the non intervention group, as well as comparing other adverse events (including but not limited to pneumonia, massive bleeding, postoperative arrhythmia, incision infection, postoperative nausea, vomiting, and delirium), all cause secondary intubation, and all cause secondary surgery between the two groups, and recording hospitalization time, ICU stay time The removal time of tracheal intubation and drainage tube, as well as the pain score during hospitalization and the total amount of opioid drug use (converted to equivalent dose morphine), hospitalization cost, postoperative recovery quality QoR15 scale score, and patient satisfaction score, were recorded to explore whether the ERAS regimen can reduce the incidence of major postoperative adverse events, improve patient prognosis, and accelerate postoperative recovery compared to traditional regimens.

Registry
clinicaltrials.gov
Start Date
October 11, 2023
End Date
December 30, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Yan Fuxia
Responsible Party
Sponsor Investigator
Principal Investigator

Yan Fuxia

principal investigator

Chinese Academy of Medical Sciences, Fuwai Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients aged 18 to 80 years
  • Patients awaiting elective cardiac surgery with cardiopulmonary bypass (CPB)

Exclusion Criteria

  • American Society of Anesthesiologists (ASA) class is above class V
  • Patients with cardiac assist device or mechanical ventilation
  • The ejection fraction of patients is less than 30%
  • Patients with morbid obesity
  • Patients with severe obstructive sleep apnea-hypopnea syndrome (OSAHS)
  • Patients with severe pulmonary disease, including severe chronic obstructive pulmonary disease (COPD) or respiratory failure
  • Patients with severe liver or renal dysfunction, including severe acute or chronic renal dysfunction need renal replacement therapy, and acute or chronic liver failure need artificial liver therapy
  • Patients with long-term opioid or sedative utilization
  • Patients with a history of alcohol or cigarette abuse
  • Patients with long-term hormone therapy

Outcomes

Primary Outcomes

Composite outcomes

Time Frame: during hospitalization, an average of 1 week, assessed up to 30 days

The composite outcomes include the major adverse cardiac and cerebrovascular events (MACCE), major postoperative pulmonary complication (PPCs), and acute kidney injury (AKI).

Secondary Outcomes

  • cumulative opioid dosage(during hospitalization, an average of 1 week, assessed up to 30 days)
  • the duration of intensive care unit (ICU) stay(Time from ICU admission to ICU discharge, assessed up to 30 days)
  • the quality of recovery score (QoR)-15 after surgery(At 24 hour after surgery)
  • length of hospital stay(From the date of admission until the date of discharging, assessed up to 30 days)
  • time to extubation(The time from the end of operation to the removal of tracheal intubation, assessed up to 30 days)
  • overall medical costs(during hospitalization, an average of 1 week, assessed up to 30 days)
  • satisfaction score(the day before discharge, assessed up to 30 days)
  • time to drainage removal(The time from the end of operation to the removal of drainage tube, assessed up to 30 days)
  • the rate of other complications(during hospitalization, an average of 1 week, assessed up to 30 days)
  • the rate of reintubation for any cause(during hospitalization, an average of 1 week, assessed up to 30 days)
  • the outcomes of long-term prognosis by telephone follow-up(within 30 days, 3 months, and 1 year)

Study Sites (1)

Loading locations...

Similar Trials